CLINICAL_TRIALS
research
· 2026-04-16
Clinical Trial Update: Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma [Phase 2]
Summary
Sanofi's Lunsekimig (SAR443765) is in Phase 2 for high-risk asthma, with recruitment ongoing in a placebo-controlled trial.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Asthma | Phase 2 | Status: RECRUITING